These PCMA talking points in opposition to CT HB5384 outline how the legislation will raise healthcare costs due to unnecessary mandates to disclose drug pricing terms by compressing rebates and discounts and may lead to tacit collusion. If Connecticut implements a PBM discolsure mandate, projected drug costs for employers and commercial health plans would increase by $635 million in the state over the next ten years.